Trump to visit Fed on Thursday amid Powell feud, renovation probe
Investing.com - Cantor Fitzgerald maintained its overweight rating on Kura Oncology (NASDAQ:KURA) stock on Friday. According to InvestingPro data, the stock is currently trading near its 52-week low of $5.41, having declined over 72% in the past year, though analysts maintain a strong bullish consensus with price targets ranging from $8 to $40.
The research firm’s decision comes as investor uncertainty around the market size for menin inhibitors and competitive dynamics among the three players in this space has pressured Kura’s shares. Despite market pressures, the company maintains a healthy financial position with a current ratio of 8.07, indicating strong short-term liquidity. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report.
The menin inhibitor market is approaching a significant milestone with potential launches into the NPM1m segment, which represents approximately 30% of acute myeloid leukemia (AML) cases, expected later this year.
These upcoming launches include revumenib from Syndax (NASDAQ:SNDX) and ziftomenib, which could provide more concrete data points to help determine the overall market size.
Cantor Fitzgerald believes these developments may offer "more tangible points to triangulate the market size," potentially addressing some of the uncertainty that has affected Kura’s stock performance.
In other recent news, Kura Oncology has been the subject of several analyst evaluations, focusing on its promising treatment for acute myeloid leukemia (AML), ziftomenib. H.C. Wainwright reiterated its buy rating with a $40 price target, citing favorable safety data from the Phase 1a/1b KOMET-007 trial, which combined ziftomenib with standard chemotherapy. This trial showed high rates of complete response and minimal residual disease negativity. Meanwhile, Cantor Fitzgerald maintained an Overweight rating, highlighting the market potential for menin inhibitors like ziftomenib and noting the pending Prescription Drug User Fee Act (PDUFA) date of November 30, 2025.
Citizens JMP also reaffirmed a Market Outperform rating with a $28 price target, emphasizing the drug’s potential regulatory approval in the fourth quarter of 2025. The firm noted Kura’s strong financial position, with a pro forma cash position of $703.2 million. Additionally, the U.S. Food and Drug Administration (FDA) has accepted Kura’s New Drug Application for ziftomenib in relapsed or refractory NPM1-mutated AML, granting it priority review status. These developments reflect significant advancements in Kura’s clinical programs as it prepares for potential market entry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.